Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2013 (2013), Article ID 148526, 12 pages
http://dx.doi.org/10.1155/2013/148526
Clinical Study

Association of Serum Adiponectin, Leptin, and Resistin Concentrations with the Severity of Liver Dysfunction and the Disease Complications in Alcoholic Liver Disease

1Department of Gastroenterology with Endoscopy Unit, Medical University of Lublin, 8 Jaczewski Street, 20-954 Lublin, Poland
2Department of Clinical Immunology, Medical University of Lublin, 4A Chodzki Street, 20-093 Lublin, Poland
3Department of Mathematics and Biostatistics, Medical University of Lublin, 4 Jaczewski Street, 20-090 Lublin, Poland

Received 28 April 2013; Revised 21 August 2013; Accepted 5 September 2013

Academic Editor: Elizabeth J. Kovacs

Copyright © 2013 Beata Kasztelan-Szczerbinska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Marra and C. Bertolani, “Adipokines in liver diseases,” Hepatology, vol. 50, no. 3, pp. 957–969, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Parola and F. Marra, “Adipokines and redox signaling: impact on fatty liver disease,” Antioxidants and Redox Signaling, vol. 15, no. 2, pp. 461–483, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Coelho, T. Oliveira, and R. Fernandes, “Biochemistry of adipose tissue: an endocrine organ,” Archives of Medical Science, vol. 9, no. 2, pp. 191–200, 2013. View at Google Scholar
  4. F. Lago, C. Dieguez, J. Gómez-Reino, and O. Gualillo, “The emerging role of adipokines as mediators of inflammation and immune responses,” Cytokine and Growth Factor Reviews, vol. 18, no. 3-4, pp. 313–325, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. M. H. Jarrar, A. Baranova, R. Collantes et al., “Adipokines and cytokines in non-alcoholic fatty liver disease,” Alimentary Pharmacology and Therapeutics, vol. 27, no. 5, pp. 412–421, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Krawczyk, P. Szczesniak, A. Kumor et al., “Adipohormones as prognostic markers in patients with nonalcoholic steatohepatitis (NASH),” Journal of Physiology and Pharmacology, vol. 60, no. 3, pp. 71–75, 2009. View at Google Scholar · View at Scopus
  7. M. Durazzo, G. Niro, A. Premoli et al., “Type 1 autoimmune hepatitis and adipokines: new markers for activity and disease progression?” Journal of Gastroenterology, vol. 44, no. 5, pp. 476–482, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. V. W.-S. Wong, G. L.-H. Wong, J. Yu et al., “Interaction of adipokines and hepatitis B virus on histological liver injury in the chinese,” The American Journal of Gastroenterology, vol. 105, no. 1, pp. 132–138, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Kukla, W. Mazur, R. J. Bułdak, and K. Zwirska-Korczala, “Potential role of leptin, adiponectin and three novel adipokines-visfatin, chemerin and vaspin-in chronic hepatitis,” Molecular Medicine, vol. 17, no. 11, pp. 1397–1410, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. T. F. Babor, J. C. Higgins-Biddle, J. B. Saunders, and M. G. Monteiro, AUDIT the Alcohol Use Disorders. Identification Test Guidelines for Use in Primary Care, World Health Organization, Geneva, Switzerland, 2nd edition, 2001.
  11. R. N. H. Pugh, I. M. Murray Lyon, and J. L. Dawson, “Transection of the oesophagus for bleeding oesophageal varices,” British Journal of Surgery, vol. 60, no. 8, pp. 646–649, 1973. View at Google Scholar · View at Scopus
  12. P. S. Kamath and W. R. Kim, “The Model for End-stage Liver Disease (MELD),” Hepatology, vol. 45, no. 3, pp. 797–805, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Ferenci, A. Lockwood, K. Mullen, R. Tarter, K. Weissenborn, and A. T. Blei, “Hepatic encephalopathy: definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998,” Hepatology, vol. 35, no. 3, pp. 716–721, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. European Association for the Study of the Liver, “EASL clinical practice guidelines: management of cholestatic liver diseases,” Journal of Hepatology, vol. 51, no. 2, pp. 237–267, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. E. H. Livingston, “Pitfalls in using BMI as a selection criterion for bariatric surgery,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 19, no. 5, pp. 347–351, 2012. View at Publisher · View at Google Scholar
  16. P. Suchanek, I. Kralova Lesna, O. Mengerova, J. Mrazkova, V. Lanska, and P. Stavek, “Which index best correlates with body fat mass: BAI, BMI, waist or WHR?” Neuro Endocrinology Letters, vol. 33, supplement 2, pp. 78–82, 2012. View at Google Scholar
  17. E. R. DeLong, D. M. DeLong, and D. L. Clarke-Pearson, “Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach,” Biometrics, vol. 44, no. 3, pp. 837–845, 1988. View at Google Scholar · View at Scopus
  18. E. F. Schisterman, N. J. Perkins, A. Liu, and H. Bondell, “Optimal cut-point and its corresponding Youden index to discriminate individuals using pooled blood samples,” Epidemiology, vol. 16, no. 1, pp. 73–81, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. B. M. Sebastian, S. Roychowdhury, H. Tang et al., “Identification of a cytochrome P4502E1/Bid/C1q-dependent axis mediating inflammation in adipose tissue after chronic ethanol feeding to mice,” The Journal of Biological Chemistry, vol. 286, no. 41, pp. 35989–35997, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. W. Zhong, Y. Zhao, Y. Tang et al., “Chronic alcohol exposure stimulates adipose tissue lipolysis in mice: role of reverse triglyceride transport in the pathogenesis of alcoholic steatosis,” The American Journal of Pathology, vol. 180, no. 3, pp. 998–1007, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Addolorato, E. Capristo, A. V. Greco, G. F. Stefanini, and G. Gasbarrini, “Influence of chronic alcohol abuse on body weight and energy metabolism: is excess ethanol consumption a risk factor for obesity or malnutrition?” Journal of Internal Medicine, vol. 244, no. 5, pp. 387–395, 1998. View at Publisher · View at Google Scholar · View at Scopus
  22. W. Kiess, S. Petzold, M. Töpfer et al., “Adipocytes and adipose tissue,” Best Practice & Research Clinical Endocrinology & Metabolism, vol. 22, no. 1, pp. 135–153, 2008. View at Publisher · View at Google Scholar
  23. S. Blüher, S. Shah, and C. S. Mantzoros, “Leptin deficiency: clinical implications and opportunities for therapeutic interventions,” Journal of Investigative Medicine, vol. 57, no. 7, pp. 784–788, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. R. L. Bracho-Riquelme, V. Loera-Castañeda, A. Torres-Valenzuela, G. A. Loera-Castañeda, and J. P. Sánchez-Ramírez, “Leptin and leptin receptor polymorphisms are associated with poor outcome (death) in patients with non-appendicular secondary peritonitis,” Critical Care, vol. 15, no. 5, article no. R227, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Röjdmark, J. Calissendorff, and K. Brismar, “Alcohol ingestion decreases both diurnal and nocturnal secretion of leptin in healthy individuals,” Clinical Endocrinology, vol. 55, no. 5, pp. 639–647, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. A. S. Aguiar-Nemer, M. C. Toffolo, C. J. da Silva, R. Laranjeira, and V. A. Silva-Fonseca, “Leptin influence in craving and relapse of alcoholics and smokers,” Journal of Clinical Medicine Research, vol. 5, no. 3, pp. 164–167, 2013. View at Google Scholar
  27. G. Dammann, J. Dierkes, M. Graf et al., “No significant effect of acute moderate alcohol intake on leptin levels in healthy male volunteers,” Addiction Biology, vol. 10, no. 4, pp. 357–364, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Campillo, E. Sherman, J. P. Richardet, and P. N. Bories, “Serum leptin levels in alcoholic liver cirrhosis: relationship with gender, nutritional status, liver function and energy metabolism,” European Journal of Clinical Nutrition, vol. 55, no. 11, pp. 980–988, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. J. M. Nicolás, J. Fernández-Solà, F. Fatjó et al., “Increased circulating leptin levels in chronic alcoholism,” Alcoholism, vol. 25, no. 1, pp. 83–88, 2001. View at Google Scholar
  30. F. Santolaria, A. Pérez-Cejas, M. R. Alemán et al., “Low serum leptin levels and malnutrition in chronic alcohol misusers hospitalized by somatic complications,” Alcohol and Alcoholism, vol. 38, no. 1, pp. 60–66, 2003. View at Publisher · View at Google Scholar
  31. A. V. Greco, G. Mingrone, A. Favuzzi et al., “Serum leptin levels in post-hepatitis liver cirrhosis,” Journal of Hepatology, vol. 33, no. 1, pp. 38–42, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. P. De Timary, P. D. Cani, J. Duchemin et al., “The loss of metabolic control on alcohol drinking in heavy drinking alcohol-dependent subjects,” PLoS ONE, vol. 7, no. 7, Article ID e38682, 2012. View at Google Scholar
  33. K. Karmiris, I. E. Koutroubakis, C. Xidakis, M. Polychronaki, T. Voudouri, and E. A. Kouroumalis, “Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 12, no. 2, pp. 100–105, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. V. A. Arvaniti, K. C. Thomopoulos, A. Tsamandas et al., “Serum adiponectin levels in different types of non alcoholic liver disease. Correlation with steatosis, necroinflammation and fibrosis,” Acta Gastro-Enterologica Belgica, vol. 71, no. 4, pp. 355–360, 2008. View at Google Scholar · View at Scopus
  35. M. Lemoine, V. Ratziu, M. Kim et al., “Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease,” Liver International, vol. 29, no. 9, pp. 1431–1438, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Xu, Y. Wang, H. Keshaw, L. Y. Xu, K. S. L. Lam, and G. J. S. Cooper, “The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice,” Journal of Clinical Investigation, vol. 112, no. 1, pp. 91–100, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Zhou, A. Xu, K. S. L. Lam et al., “Rosiglitazone promotes fatty acyl CoA accumulation and excessive glycogen storage in livers of mice without adiponectin,” Journal of Hepatology, vol. 53, no. 6, pp. 1108–1116, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. V. Thakur, M. T. Pritchard, M. R. McMullen, and L. E. Nagy, “Adiponectin normalizes LPS-stimulated TNF-α production by rat Kupffer cells after chronic ethanol feeding,” American Journal of Physiology: Gastrointestinal and Liver Physiology, vol. 290, no. 5, pp. G998–G1007, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. A. M. Brennan, T. Y. Li, I. Kelesidis, A. Gavrila, F. B. Hu, and C. S. Mantzoros, “Circulating leptin levels are not associated with cardiovascular morbidity and mortality in women with diabetes: a prospective cohort study,” Diabetologia, vol. 50, no. 6, pp. 1178–1185, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. R. Faggioni, G. Fantuzzi, J. Fuller, C. A. Dinarello, K. R. Feingold, and C. Grunfeld, “Leptin deficiency enhances sensitivity to endotoxin-induced lethality,” American Journal of Physiology: Regulatory Integrative and Comparative Physiology, vol. 276, no. 1, pp. R136–R142, 1999. View at Google Scholar · View at Scopus
  41. N. Takahashi, W. Waelput, and Y. Guisez, “Leptin is an endogenous protective protein against the toxicity exerted by tumor necrosis factor,” Journal of Experimental Medicine, vol. 189, no. 1, pp. 207–212, 1999. View at Publisher · View at Google Scholar · View at Scopus
  42. W. Wang, B. Poole, A. Mitra et al., “Role of leptin deficiency in early acute renal failure during endotoxemia in ob/ob mice,” Journal of the American Society of Nephrology, vol. 15, no. 3, pp. 645–649, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Axelsson, A. Bergsten, A. R. Qureshi et al., “Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance,” Kidney International, vol. 69, no. 3, pp. 596–604, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. R. Kawamura, Y. Doi, H. Osawa et al., “Circulating resistin is increased with decreasing renal function in a general Japanese population: the Hisayama Study,” Nephrology Dialysis Transplantation, vol. 25, no. 10, pp. 3236–3240, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. J. T. Kielstein, B. Becker, S. Graf, G. Brabant, H. Haller, and D. Fliser, “Increased resistin blood levels are not associated with insulin resistance in patients with renal disease,” American Journal of Kidney Diseases, vol. 42, no. 1, pp. 62–66, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. C. Menzaghi, L. Salvemini, G. Fini et al., “Serum resistin and kidney function: a family-based study in non-diabetic, untreated individuals,” PLoS ONE, vol. 7, no. 6, Article ID e38414, 2012. View at Google Scholar
  47. W. Chung, E. S. Jung, D. Shin et al., “Low resistin level is associated with poor hospitalization-free survival in hemodialysis patients,” Journal of Korean Medical Science, vol. 27, no. 4, pp. 377–381, 2012. View at Publisher · View at Google Scholar
  48. D. S. Frankel, R. S. Vasan, R. B. D'Agostino Sr. et al., “Resistin, Aadiponectin, and risk of heart Ffailure: the Framingham Offspring Study,” Journal of the American College of Cardiology, vol. 53, no. 9, pp. 754–762, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Karpavicius, Z. Dambrauskas, A. Sileikis, D. Vitkus, and K. Strupas, “Value of adipokines in predicting the severity of acute pancreatitis: comprehensive review,” World Journal of Gastroenterology, vol. 18, no. 45, pp. 6620–6627, 2012. View at Publisher · View at Google Scholar
  50. A. Koch, E. Sanson, S. Voigt, A. Helm, C. Trautwein, and F. Tacke, “Serum adiponectin upon admission to the intensive care unit may predict mortality in critically ill patients,” Journal of Critical Care, vol. 26, no. 2, pp. 166–174, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. D. Macis, S. Gandini, A. Guerrieri-Gonzaga et al., “Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer,” Journal of Clinical Oncology, vol. 30, no. 2, pp. 151–157, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. T. Tsutamoto, T. Tanaka, H. Sakai et al., “Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure,” European Heart Journal, vol. 28, no. 14, pp. 1723–1730, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. A. L. Beatty, M. H. Zhang, I. A. Ku, B. Na, N. B. Schiller, and M. A. Whooley, “Adiponectin is associated with increased mortality and heart failure in patients with stable ischemic heart disease: data from the Heart and Soul Study,” Atherosclerosis, vol. 220, no. 2, pp. 587–592, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. G. Fantuzzi, “Adipose tissue, adipokines, and inflammation,” Journal of Allergy and Clinical Immunology, vol. 115, no. 5, pp. 911–920, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Filková, H. Hulejová, K. Kuncová et al., “Resistin in idiopathic inflammatory myopathies,” Arthritis Research & Therapy, vol. 14, no. 3, article R111, 2012. View at Publisher · View at Google Scholar
  56. L. Li and L. L. Wu, “Adiponectin and interleukin-6 in inflammation-associated disease,” Vitamins & Hormones, vol. 90, pp. 375–395, 2012. View at Publisher · View at Google Scholar
  57. T. Yoshino, N. Kusunoki, N. Tanaka et al., “Elevated serum levels of resistin, leptin, and adiponectin are associated with c-reactive protein and also other clinical conditions in rheumatoid arthritis,” Internal Medicine, vol. 50, no. 4, pp. 269–275, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. K. Ohashi, N. Ouchi, and Y. Matsuzawa, “Anti-inflammatory and anti-atherogenic properties of adiponectin,” Biochimie, vol. 94, no. 10, pp. 2137–2142, 2012. View at Publisher · View at Google Scholar
  59. M. Blüher, “Clinical relevance of adipokines,” Diabetes & Metabolism Journal, vol. 36, no. 5, pp. 317–327, 2012. View at Publisher · View at Google Scholar
  60. Y. Deng and P. E. Scherer, “Adipokines as novel biomarkers and regulators of the metabolic syndrome,” Annals of the New York Academy of Sciences, vol. 1212, pp. E1–E19, 2010. View at Google Scholar · View at Scopus
  61. S. Lehr, S. Hartwig, and H. Sell, “Adipokines: a treasure trove for the discovery of biomarkers for metabolic disorders,” Proteomics Clinical Applications, vol. 6, no. 1-2, pp. 91–101, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. E. Maury and S. M. Brichard, “Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome,” Molecular and Cellular Endocrinology, vol. 314, no. 1, pp. 1–16, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. G. Tarantino, S. Savastano, and A. Colao, “Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance,” World Journal of Gastroenterology, vol. 16, no. 38, pp. 4773–4783, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. G. Fantuzzi, “Adiponectin and inflammation: consensus and controversy,” Journal of Allergy and Clinical Immunology, vol. 121, no. 2, pp. 326–330, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. C. Popa, M. G. Netea, J. de Graaf et al., “Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis,” Journal of Rheumatology, vol. 36, no. 4, pp. 724–730, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. C. J. Behre, “Adiponectin: saving the starved and the overfed,” Medical Hypotheses, vol. 69, no. 6, pp. 1290–1292, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. Kemmotsu, T. Saji, N. Kusunoki et al., “Serum adipokine profiles in Kawasaki disease,” Modern Rheumatology, vol. 22, no. 1, pp. 66–72, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. A. Trzeciak-Ryczek, B. Tokarz-Deptula, and W. Deptuła, “Adipocytokines affecting the immune system: selected data,” Central European Journal of Immunology, vol. 36, no. 2, pp. 92–94, 2011. View at Google Scholar · View at Scopus
  69. R. M. Lorente Ramos, J. Azpeitia Armán, N. Arévalo Galeano, A. Muñoz Hernández, J. M. García Gómez, and J. Gredilla Molinero, “Dual energy X-ray absorptimetry: fundamentals, methodology, and clinical applications,” Radiología, vol. 54, no. 5, pp. 410–423, 2012. View at Publisher · View at Google Scholar
  70. W. C. Kerr and T. Stockwell, “Understanding standard drinks and drinking guidelines,” Drug and Alcohol Review, vol. 31, no. 2, pp. 200–205, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. T. Stockwell and L. Stirling, “Estimating alcohol content of drinks: common errors in applying the unit system,” British Medical Journal, vol. 298, no. 6673, pp. 571–572, 1989. View at Google Scholar · View at Scopus